Orchestra BioMed (OBIO) Insider Prosper Buys 34,653 Shares
Mack John Prosper picked up 34,653 shares of Orchestra BioMed Holdings, Inc. on June 23, 2026, joining several other insiders in expanding their holdings.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mack John Prosper bought 34,653 shares of Orchestra BioMed Holdings, Inc. ($OBIO) on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OBIO is up 6.9% after 1 week, down 9.9% after 1 month and up 34.9% to date (from the $4.04 close on Jun 23, 2026).
OBIO
Orchestra BioMed Holdings, Inc.
Key Points
- Mack John Prosper acquired 34,653 shares of Orchestra BioMed Holdings, Inc. on June 23, 2026.
- The transaction formed part of a coordinated group of insider purchases executed on the same date by multiple company figures.
- Wall Street analysts maintain an overall strong buy recommendation on the stock with a mean price target of $12.14.
Get $OBIO trade alerts by text
We text you when insiders, Congress or big funds trade $OBIO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Orchestra BioMed Holdings, Inc. alert may contain errors. Disclosures
Mack John Prosper Expands Position in Orchestra BioMed Holdings
Mack John Prosper picked up 34,653 shares of Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO) on June 23, 2026. This transaction added to an active period of internal activity at the biomedical firm, arriving alongside several other leadership purchases on the exact same day.
A Coordinated Wave of Insider Purchases
The acquisition by Mack John Prosper was just one piece of a broader wave of buying activity across the company on June 23, 2026. Other key participants also added to their holdings on that date. Jason Aryeh secured 42,553 shares, while Chris Cleary picked up an identical block of 42,553 shares. David Pacitti engaged in two separate transactions, acquiring 21,277 shares and another 17,327 shares. Pamela Ann Connealy rounded out the group by purchasing 17,327 shares.
Recent Stock Price and Market Context
Shares of Orchestra BioMed trade on the NasdaqGM exchange under the ticker OBIO, with the spot price sitting near $3.90. The equity has moved between a 52-week low of $2.20 and a 52-week high of $6.30. The company maintains a market capitalization of $375.66 million, reflecting its position within the healthcare sector.
Analysts Set New Price Targets
Financial firms following the organization have adjusted their expectations in recent months. On August 11, 2026, Piper Sandler reiterated an overweight rating while adjusting its price target to $10.00 from $9.00. Later, on September 10, 2026, BTIG upgraded the equity to a buy rating with a $10.00 price target. Shortly after, on September 15, 2026, B. Riley Securities maintained a buy rating and lifted its target to $11.00 from $10.00. Overall, the stock carries a consensus strong buy recommendation and a mean price target of $12.14 across seven analyst opinions.
Company Focus and Operations
Based in New Hope, Pennsylvania, Orchestra BioMed Holdings, Inc. operates as a late-stage biomedical company focused on therapeutic solutions for chronic diseases. Its pipeline includes bioelectronic therapies and catheter-based products designed to lower blood pressure and treat cardiovascular conditions through strategic collaborations with larger medical device manufacturers.
What to Watch at Orchestra BioMed Holdings, Inc.
Investors monitoring the company can look toward the next scheduled earnings report on November 5, 2026, for further updates on clinical trials and pipeline progress. Insider transactions provide a look into how leadership views the business, though these filings capture only specific moments in time rather than ongoing market strategies.
Related Filing Alerts
Source: Mack John Prosper's Form 4 filing on $OBIO (Jun 23, 2026). Find the original filing: OBIO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts